Tag: drug price transparency

drug price transparency

DTC Advertising

Patients: DTC Ad Drug Price Transparency Proposed Rule Needs More Context, Expanded Scope

Patients: DTC Ad Drug Price Transparency Proposed Rule Needs More Context, Expanded Scope

Feb. 5, 2019 – Patient and disease advocacy groups have weighed in on the Centers for Medicare & Medicaid Services (CMS) proposal to require that drug companies list the wholesale acquisition cost (WAC) for their drugs in televised direct-to-consumer (DTC) ads. Their comments to CMS raise issues about whether the proposed rule asks for disclosure […]

Read more

DTC Advertising

Many Physician Groups Call for Broader DTC Ad Price Disclosure, Greater Penalties for Violators

Many Physician Groups Call for Broader DTC Ad Price Disclosure, Greater Penalties for Violators

Jan. 29, 2019 — Although industry trade groups filing comments on the Centers for Medicare & Medicaid Services (CMS) proposal to require including the wholesale acquisition cost (WAC) in television ads for prescription drugs were largely agreed in their positions against the idea (as reported here), comments from physician organizations and specialty groups were more […]

Read more

DTC Advertising

NEJM: Drug Price Information in DTC Ads Raises Public Health, Legal Concerns

NEJM: Drug Price Information in DTC Ads Raises Public Health, Legal Concerns

Nov. 19, 2018 – In a featured “Perspective” article in The New England Journal of Medicine (NEJM) this week, Stacie B. Dusetzina, Ph.D., and Michelle M. Mello, J.D., Ph.D., state that although providing cost information about prescription drugs is valuable, mandating that companies use the wholesale acquisition cost (WAC) in direct-to-consumer (DTC) ads “raises substantial […]

Read more

DTC Advertising

Senate and HHS Make Moves to Advance Mandatory Drug Prices in Consumer Ads

Senate and HHS Make Moves to Advance Mandatory Drug Prices in Consumer Ads

Aug. 24, 2018 – Yesterday was a one-two punch in the Trump administration’s effort to move forward a plan to require that drug manufacturers include drug prices in ads directed toward consumers, as the White House Office of Management and Budget (OMB) reviews a proposed rule from the Department of Health & Human Services (HHS) […]

Read more

DTC Advertising

Debate over Listing Drug Prices in Ads Continues

Debate over Listing Drug Prices in Ads Continues

May 21, 2018 – Since the Trump administration presented its proposal to lower drug pricing on May 11, both the trade and mainstream media have been discussing whether one provision – a request that the Department of Health & Human Services evaluate the inclusion of drug prices in consumer ads – really has legs. In […]

Read more

Washington Focus

White House Plan to Lower Drug Prices Takes Incremental Approach

White House Plan to Lower Drug Prices Takes Incremental Approach

May 14, 2018 – President Donald Trump on Friday announced his blueprint to lower drug prices, but his initiatives were deemed “a raft of modest moves that left the pharmaceutical industry relieved and buoyed their stocks,” by The Wall Street Journal. One of the more controversial items in Trump’s plan is a request that the Department […]

Read more